跳至主要内容
临床试验/NCT00716443
NCT00716443终止4 期

Open-Label, Randomized, Split-Face Study to Evaluate the Efficacy, Safety and Subject Satisfaction of Pain Management During and After Restylane® Dermal Filler Injections for the Correction of Nasolabial Folds

Galderma R&D4 个研究点 分布在 1 个国家目标入组 51 人开始时间: 2008年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
发起方
Galderma R&D
入组人数
51
试验地点
4
主要终点
Subject's Pain Evaluation by Visual Analog Scale (VAS)Upon First Needlestick, Immediately After Injection, One Hour After Injection and Three Hours After Injection of Restylane® Into the Nasolabial Folds

研究概览

简要总结

Pliaglis® Cream versus compounded topical anesthetic for pain management during Restylane® injections for the correction of nasolabial folds.

详细描述

Open-label, randomized study designed to assess the effectiveness of a topical anesthetic (Pliaglis® Cream) versus a compounded topical anesthetic at needle stick, immediately after, one and three hours after Restylane® injections in the nasolabial folds.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
30 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or Female Subjects 30 - 65 years of age
  • Subject undergoing cosmetic dermal filler injections for correction of nasolabial folds. Treatment sites should be comparable, requiring the same number of injections on each nasolabial fold
  • Subjects diagnosed with moderate nasolabial folds (Wrinkle Severity Rating Scale of grade 3)

排除标准

  • Subjects under treatment for a dermatologic condition on the face, which may interfere with the safe evaluation of the study treatment (e.g. eczema, psoriasis, severe sun-damage, dermatitis), have damaged, denuded or broken skin at the designated treatment site and/or have scarring or infection of the area to be treated
  • Subjects who have taken prescription or non-prescription analgesic medication during the 24 hour period prior to the procedure
  • Subjects with a history of bleeding or clotting disorders
  • Subjects who have used ASA (aspirin), NSAIDs (Non-Steroidal Anti- inflammatory Drugs), anticoagulants, St. John's Wort or high doses of Vitamin E (above the recommended daily allowance) within 2 weeks prior to the procedure

研究组 & 干预措施

Pliaglis® Cream

Active Comparator

tetracaine 4% / lidocaine 7% cream; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.

干预措施: tetracaine 7% / lidocaine 7% cream (Pliaglis® Cream) (Drug)

Pliaglis® Cream

Active Comparator

tetracaine 4% / lidocaine 7% cream; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.

干预措施: benzocaine 20% / lidocaine 6% / tetracaine 4% ointment (Drug)

benzocaine 20% / lidocaine 6% / tetracaine 4% ointment

Active Comparator

apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.

干预措施: benzocaine 20% / lidocaine 6% / tetracaine 4% ointment (Drug)

结局指标

主要结局

Subject's Pain Evaluation by Visual Analog Scale (VAS)Upon First Needlestick, Immediately After Injection, One Hour After Injection and Three Hours After Injection of Restylane® Into the Nasolabial Folds

时间窗: upon first needlestick, immediately after injection, one hour after injection and three hours after injection of Restylane® into the nasolabial folds

Subject's pain as evaluated using a VAS scale from 0 - 10 cm (centimeters) with 0 cm being no pain and 10 cm being the worst pain imaginable upon first needlestick, immediately after injection, one hour after injection and three hours after injection of Restylane® into the nasolabial folds

次要结局

  • Number of Participants Who Answered the Question "If You Experienced Pain, Was it What You Expected From the Injection Procedure?" Three Hours After Injection of Restylane® Into the Nasolabial Folds(three hours after injection of Restylane® into the nasolabial folds)
  • Number of Participants in Each Category of the Investigator Evaluation of the Subject's Post Procedure Pain Assessment Scale Immediately After Injection of Restylane® Into the Nasolabial Folds(immediately after injection of Restylane® into the nasolabial folds)
  • Number of Participants in Each Category of the Investigator's Evaluation of Subject's Pain Scale Three Hours After Injection of Restylane® Into the Nasolabial Folds(three hours after injection of Restylane® into the nasolabial folds)
  • Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale Upon First Needle Stick of Injection of Restylane® Into the Nasolabial Folds(upon first needle stick of injection of Restylane® into the nasolabial folds)
  • Number of Participants Who Answered the Question "If it Was Different Than What You Expected, Was it?" Three Hours After Injection of Restylane® Into the Nasolabial Folds(three hours after injection of Restylane® into the nasolabial folds)
  • Number of Participants in Each Category of the Investigator's Evaluation of Subject's Pain Scale One Hour After Injection of Restylane® Into the Nasolabial Folds(one hour after injection of Restylane® into the nasolabial folds)
  • Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale One Hour After Injection of Restylane® Into the Nasolabial Folds(one hour after injection of Restylane® into the nasolabial folds)
  • Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale Immediately After Injection of Restylane® Into the Nasolabial Folds(immediately after injection of Restylane® into the nasolabial folds)
  • Number of Participants With Tolerability Assessments Resulting in Adverse Events From Baseline to Two Days After Injection of Restylane® Into the Nasolabial Folds(Baseline to two days after injection of Restylane® into the nasolabial folds)
  • Number of Participants Who Answered the Question "What Level of Pain Did You Experience When You Were Injected?" Three Hours After Injection of Restylane® Into the Nasolabial Folds(three hours after injection of Restylane® into the nasolabial folds)
  • Number of Participants Who Answered the Question "Still Speaking to the Topical Anesthetic You Had on the Right/Left Side of Your Face, Would You Recommend it to Your Friend or Family Member?" 3 Hours After Injection of Restylane® Into Nasolabial Folds(three hours after injection of Restylane® into the nasolabial folds)
  • Number of Participants in Each Category of the Investigator Evaluation of the Subject's Post Procedure Pain Assessment Scale Upon First Needle Stick of Injection of Restylane® Into the Nasolabial Folds(Upon first needle stick of injection of Restylane® into the nasolabial folds)
  • Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale Three Hours After Injection of Restylane® Into the Nasolabial Folds(three hours after injection of Restylane® into the nasolabial folds)
  • Number of Participants With Yes/no Answers to Question to Investigator "Did the Topical Anesthetics Provide Adequate Anesthesia for the Injections of Restylane® Into the Nasolabial Folds Procedure?" Day of Injection of Restylane® Into Nasolabial Folds(Day of injection of Restylane® into the nasolabial folds)

研究者

发起方
Galderma R&D
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验